Opus Genetics, Inc. (IRD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.20 (-1.52%), Market cap $0.36B, 52-week low–high $0.91 ~ $5.75.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterio
Financial statements, price targets, institutional (13F) holdings and related news for Opus Genetics, Inc. are updated in real time on BlackAll Trade.
Opus Genetics, Inc. trades at $5.20 (-1.52%). Real-time quotes and charts are available on BlackAll Trade.
Opus Genetics, Inc. has a market cap of about $0.36B.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of t